Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Interest Expenses (2016 - 2019)

Vistagen Therapeutics' Interest Expenses history spans 8 years, with the latest figure at -$1500.0 for Q4 2019.

  • For Q4 2019, Interest Expenses fell 183.33% year-over-year to -$1500.0; the TTM value through Sep 2020 reached -$1500.0, down 131.25%, while the annual FY2018 figure was $8900.0, 93.48% up from the prior year.
  • Interest Expenses for Q4 2019 was -$1500.0 at Vistagen Therapeutics, down from $1800.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $755000.0 in Q2 2015 and bottomed at -$1500.0 in Q4 2019.
  • The 5-year median for Interest Expenses is $2000.0 (2016), against an average of $52620.0.
  • The largest annual shift saw Interest Expenses soared 200.0% in 2017 before it plummeted 183.33% in 2019.
  • A 5-year view of Interest Expenses shows it stood at $3000.0 in 2015, then crashed by 66.67% to $1000.0 in 2016, then skyrocketed by 100.0% to $2000.0 in 2017, then dropped by 10.0% to $1800.0 in 2018, then tumbled by 183.33% to -$1500.0 in 2019.
  • Per Business Quant, the three most recent readings for VTGN's Interest Expenses are -$1500.0 (Q4 2019), $1800.0 (Q4 2018), and $3000.0 (Q3 2018).